|1.||Kroll, Stewart: 3 articles (04/2010 - 05/2008)|
|2.||Langmuir, Virginia K: 3 articles (04/2010 - 05/2008)|
|3.||Briasoulis, E: 3 articles (03/2004 - 10/2000)|
|4.||Fumoleau, P: 3 articles (03/2004 - 11/2003)|
|5.||Lacombe, D: 3 articles (03/2004 - 11/2003)|
|6.||Opydo-Chanek, Małgorzata: 2 articles (07/2011 - 01/2010)|
|7.||Mazur, Lidia: 2 articles (07/2011 - 01/2010)|
|8.||Stojak, Marta: 2 articles (07/2011 - 01/2010)|
|9.||Jung, Donald T: 2 articles (04/2010 - 05/2008)|
|10.||Loehrer, Patrick J: 2 articles (04/2010 - 05/2008)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
11/01/2003 - "Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. "
11/01/2003 - "The activity of glufosfamide (beta-D-glucopyranosyl-N,N'-di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. "
01/01/2005 - "In December 2004, Threshold initiated a phase I/II trial (TH-CR-301 Study) investigating glufosfamide in combination with gemcitabine as a first-line treatment of pancreatic cancer or advanced solid tumours. "
04/01/2010 - "The combination of glufosfamide plus gemcitabine is active in pancreatic cancer; however, hematologic and renal toxicity were pronounced. "
08/01/2007 - "We studied the effects of glufosfamide, in combination with gemcitabine, on in vitro and in vivo models of pancreatic cancer. "
07/01/2011 - "Glufosfamide represents an attractive new agent for cancer therapy. "
01/01/2005 - "Glufosfamide was originally developed from a research collaboration between Asta Medica (Degussa) and the Cancer Research Centre (DKFZ) in Heidelberg, Germany. "
03/01/2004 - "Patients were treated with 5000 mg/m(2) glufosfamide by a 1-h intravenous (i.v.) infusion every 3 weeks following registration at the European Organisation for Research and Treatment of Cancer (EORTC) Data Center. "
01/01/2002 - "Glufosfamide is a new agent for cancer chemotherapy. "
12/01/2003 - "European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme."
11/01/2003 - "In conclusion, glufosfamide administered using a 1-h infusion every 3 weeks has a modest activity in advanced pancreatic adenocarcinoma. "
06/01/2009 - "A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine."
04/01/2010 - "A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma."
05/01/2008 - "A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma."
01/01/2002 - "The aim of the study was a comparison of the drug resistance profiles of glufosfamide and other oxazaphosphorines in childhood acute leukemias. "
01/01/2002 - "The objective of the study was the comparison of the in vitro drug resistance profile of glufosfamide with other oxazaphosphorines in 106 samples of childhood acute leukemia by means of the MTT assay. "
01/01/2002 - "In vitro activity of glufosfamide in childhood acute leukemia."
01/01/2007 - "Phase II studies of glufosfamide in the treatment of pancreatic cancer, non-small cell lung cancer (NCSLC), and recurrent glioblastoma multiform (GBM) have recently completed and Phase III trials are ongoing, while Phase I studies of intrathecal mafosfamide have recently completed for the treatment of meningeal malignancy secondary to leukemia, lymphoma, or solid tumors. "
01/01/2005 - ", glufosfamide had been in phase II trials among patients with pancreatic carcinoma in Germany with Baxter Oncology and with the EORTC in the UK as well as Greece. "
10/15/2000 - "Evidence of antitumor activity in resistant carcinomas warrants further clinical exploration of glufosfamide in phase II studies."
08/01/2007 - "These results support the use of the alkylating agent glufosfamide and the DNA synthesis inhibitor gemcitabine, rather than the use of either agent alone, to provide greater benefits and demonstrate that this combination treatment should be useful in the clinical treatment of pancreatic carcinoma."
02/01/2000 - "In the breast carcinoma cell line MCF7 glufosfamide inhibited both the synthesis of DNA and protein in a dose-dependent manner, as shown by the decreased incorporation of [3H-methyl]-thymidine into DNA and [14C]-methionine into protein of these cells. "
|4.||isophosphamide mustard (IPAM)
|6.||Asta Z 7557
|7.||glucosyl-ifosfamide mustard (glufosfamide)
|8.||Facilitative Glucose Transport Proteins (Glucose Transporter)
|10.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)